JP2007522142A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007522142A5 JP2007522142A5 JP2006551827A JP2006551827A JP2007522142A5 JP 2007522142 A5 JP2007522142 A5 JP 2007522142A5 JP 2006551827 A JP2006551827 A JP 2006551827A JP 2006551827 A JP2006551827 A JP 2006551827A JP 2007522142 A5 JP2007522142 A5 JP 2007522142A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- heterocyclyl
- solvate
- alkyl
- functional derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000012453 solvate Substances 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 5
- 229910052736 halogen Inorganic materials 0.000 claims 5
- 150000002367 halogens Chemical class 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- -1 1H-benzoimidazol-1-yl Chemical group 0.000 claims 4
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 2
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 125000004994 halo alkoxy alkyl group Chemical group 0.000 claims 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 230000037380 skin damage Effects 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- CUPOOAWTRIURFT-UHFFFAOYSA-N thiophene-2-carbonitrile Chemical compound N#CC1=CC=CS1 CUPOOAWTRIURFT-UHFFFAOYSA-N 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0402809.8A GB0402809D0 (en) | 2004-02-09 | 2004-02-09 | Chemical compounds |
| PCT/EP2005/001432 WO2005075465A1 (en) | 2004-02-09 | 2005-02-07 | Benzimidazol substituted thiopene derivatives with atctivity on ikk3 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007522142A JP2007522142A (ja) | 2007-08-09 |
| JP2007522142A5 true JP2007522142A5 (enExample) | 2007-11-22 |
Family
ID=31985899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006551827A Pending JP2007522142A (ja) | 2004-02-09 | 2005-02-07 | Ｉｋｋ３に対して活性を有するベンゾイミダゾール置換チオフェン誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20070149519A1 (enExample) |
| EP (1) | EP1720864B1 (enExample) |
| JP (1) | JP2007522142A (enExample) |
| AT (1) | ATE430743T1 (enExample) |
| DE (1) | DE602005014341D1 (enExample) |
| ES (1) | ES2324879T3 (enExample) |
| GB (1) | GB0402809D0 (enExample) |
| WO (1) | WO2005075465A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005037827A1 (en) | 2003-10-16 | 2005-04-28 | Smithkline Beecham Corporation | Process for preparing benzimidazole thiophenes |
| JP2007519720A (ja) * | 2004-01-28 | 2007-07-19 | スミスクライン ビーチャム コーポレーション | チアゾール化合物 |
| EP1741709A1 (en) | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals |
| AR055616A1 (es) | 2005-09-06 | 2007-08-29 | Smithkline Beecham Corp | Compuestos de tiofeno bencimidazol |
| JP5498703B2 (ja) | 2006-01-23 | 2014-05-21 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なチオフェン−カルボキサミド |
| EP2418210A1 (en) | 2006-04-13 | 2012-02-15 | Vertex Pharmceuticals Incorporated | Thiophene-carboxamides useful as inhibitors of protein kinases |
| WO2007139795A1 (en) | 2006-05-23 | 2007-12-06 | Vertex Pharmaceuticals Incorporated | Thiophene-carboxamides useful as inhibitors of protein kinases |
| JP2009538309A (ja) | 2006-05-23 | 2009-11-05 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なチオフェンカルボキサミド |
| US7615643B2 (en) | 2006-06-02 | 2009-11-10 | Smithkline Beecham Corporation | Benzimidazole thiophene compounds |
| JP2009539770A (ja) * | 2006-06-02 | 2009-11-19 | スミスクライン ビーチャム コーポレーション | Ｐｌｋに対する活性を有するベンゾイミダゾール置換チオフェン誘導体 |
| CA2719247C (en) * | 2008-03-25 | 2017-03-21 | The Regents Of The University Of Michigan | Ikki inhibitor therapies and screening methods, and related ikki diagnostics |
| KR20130065632A (ko) * | 2010-04-28 | 2013-06-19 | 다이이찌 산쿄 가부시키가이샤 | ［５，６］복소 고리 화합물 |
| EP2675275B1 (en) | 2011-02-14 | 2017-12-20 | The Regents Of The University Of Michigan | Compositions and methods for the treatment of obesity and related disorders |
| GB201114051D0 (en) | 2011-08-15 | 2011-09-28 | Domainex Ltd | Compounds and their uses |
| US8946424B2 (en) | 2013-05-02 | 2015-02-03 | The Regents Of The University Of Michigan | Deuterated amlexanox |
| TW201613916A (en) | 2014-06-03 | 2016-04-16 | Gilead Sciences Inc | TANK-binding kinase inhibitor compounds |
| JP6499282B2 (ja) | 2014-09-26 | 2019-04-10 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔａｎｋ結合キナーゼ阻害剤化合物として有用なアミノトリアジン誘導体 |
| US10435375B2 (en) | 2015-05-05 | 2019-10-08 | Northwestern University | CXCR4 chemokine receptor modulators |
| US9987242B2 (en) | 2015-05-05 | 2018-06-05 | Northwestern University | Treatment of Levodopa-induced Dyskinesias |
| CU20180059A7 (es) | 2015-12-17 | 2018-10-04 | Gilead Sciences Inc | Compuestos inhibidores de la quinasa de unión a tank |
| EP3407974A4 (en) | 2016-01-29 | 2019-08-28 | The Regents Of The University Of Michigan | Amlexanox Analogs |
| US11246871B2 (en) | 2016-07-15 | 2022-02-15 | Northwestern University | Targeting adenosine A2A receptors for the treatment of levodopa-induced dyskinesias |
| DE102016113714A1 (de) | 2016-07-26 | 2018-02-01 | Rosa Karl | Transfektionsverfahren mit nicht-viralen Genliefersystemen |
| US11554103B2 (en) | 2016-11-10 | 2023-01-17 | Northwestern University | Compositions and methods to reduce pharmaceutical-induced toxicity |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5990146A (en) * | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
| CA2341409A1 (en) * | 1998-08-31 | 2000-03-09 | Merck And Co., Inc. | Novel angiogenesis inhibitors |
| DE19928424A1 (de) * | 1999-06-23 | 2000-12-28 | Aventis Pharma Gmbh | Substituierte Benzimidazole |
| WO2002076985A1 (en) * | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
| ATE414697T1 (de) * | 2001-10-04 | 2008-12-15 | Smithkline Beecham Corp | Nf-kb-inhibitoren |
| BR0313160A (pt) * | 2002-08-08 | 2005-07-12 | Smithkline Beecham Corp | Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto |
-
2004
- 2004-02-09 GB GBGB0402809.8A patent/GB0402809D0/en not_active Ceased
-
2005
- 2005-02-07 ES ES05707356T patent/ES2324879T3/es not_active Expired - Lifetime
- 2005-02-07 WO PCT/EP2005/001432 patent/WO2005075465A1/en not_active Ceased
- 2005-02-07 JP JP2006551827A patent/JP2007522142A/ja active Pending
- 2005-02-07 DE DE602005014341T patent/DE602005014341D1/de not_active Expired - Lifetime
- 2005-02-07 EP EP05707356A patent/EP1720864B1/en not_active Expired - Lifetime
- 2005-02-07 US US10/597,828 patent/US20070149519A1/en not_active Abandoned
- 2005-02-07 AT AT05707356T patent/ATE430743T1/de not_active IP Right Cessation